What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2026-07-30 compared with 2026-04-30 · 28 added, 57 removed, 20 unchanged (81% of the section changed)

OTHER INFORMATION

(a) (i) Effective May 1, 2025, the Company entered into Amended and Restated Employment Agreements (the “Employment Agreements”) with each of Raul Parra, our Chief Financial Officer, Brian G.

Lloyd, our Chief Legal Officer, Neil W.

Peterson, our Chief Operating Officer, and Michel J.

Voigt, our Chief Human Resources Officer, copies of which are filed herewith as Exhibits 10.2 through 10.5.

Material terms of the Employment Agreements are summarized in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on March 31, 2026 (the “Proxy Statement”), including without limitation in the sections entitled “Employment Agreements” beginning on page 54 and “Potential Payments Upon Termination or Change In Control” beginning on page 66, which are incorporated herein by this reference.

(ii) Effective February 26, 2026, the Company entered into Performance Stock Unit Award Agreements (the “PSU Agreements”), and Restricted Stock Unit Award Agreements (the “RSU Agreements”), with each of Martha G.

Aronson, our Chief Executive Officer, Raul Parra, our Chief Financial Officer, Brian G.

Lloyd, our Chief Legal Officer, Neil W.

Peterson, our Chief Operating Officer, and Michel J.

Voigt, our Chief Human Resources Officer, each of which is on terms and conditions consistent with the Company’s previously filed 2018 Equity Incentive Plan, as amended to date, and previously filed standard forms of agreement for grants of performance stock units and restricted stock units.

Nevertheless, copies of the PSU Agreements and RSU Agreements are filed herewith as Exhibits 10.6 through 10.15.

(iii) Effective February 26, 2026, the Company entered into Restricted Stock Unit Award Agreements (the “Retention RSU Agreements”) with each of Raul Parra, our Chief Financial Officer, Brian G.

Lloyd, our Chief Legal Officer, and Michel J.

Voigt, our Chief Human Resources Officer, each of which is on terms and conditions consistent with the

Company’s previously filed 2018 Equity Incentive Plan, as amended to date, and previously filed standard forms of agreement for grants of restricted stock units.

Nevertheless, copies of the Retention RSU Agreements are filed herewith as Exhibits 10.16 and 10.17.

(b) None of our directors or officers informed us of the adop tion or termi nation of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, during the three-month period ended March 31, 2026.

(a) On July 27, 2026, we executed a First Amendment to the Merit Medical Systems, Inc.

2026 Equity Incentive Plan (the “Plan Amendment”), which modifies the Merit Medical Systems, Inc.

2026 Equity Incentive Plan (the “Plan”).

Under the Plan, acceleration of vesting is generally not permitted unless (i) a change of control has occurred, and (ii) a “Qualifying Termination” has occurred.

The original definition of “Qualifying Termination” was specific to employees.

The effect of the Plan Amendment is to expand the definition of “Qualifying Termination” to address events that would constitute a “Qualifying Termination” for non-employee directors and consultants.

This summary is qualified by the Plan Amendment, which is incorporated herein by reference and filed as Exhibit 10.2 to this Report.

(c) On May 26, 2026 , Raul Parra , our Chief Financial Officer and Treasurer, adopted a trading arrangement (the “Parra Rule 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).

The Parra Rule 10b5-1 Trading Plan provides for the sale of up to 50,646 shares of Common Stock issued or issuable under the terms of certain stock options and performance share awards granted to Mr.

Parra by Merit.

The Parra Rule 10b5-1 Trading Plan will terminate on May 26, 2028 , unless terminated earlier pursuant to the terms of the Parra Rule 10b5-1 Trading Plan.

On May 21, 2026 , Brian G.

Lloyd , our Chief Legal Officer and Corporate Secretary, adopted a trading arrangement (the “Lloyd Rule 10b5-1 Trading Plan”) for the sale of Common Stock that is intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c).

The Lloyd Rule 10b5-1 Trading Plan provides for the sale of up to 16,722 shares of Common Stock issuable under the terms of certain stock options granted to Mr.

Lloyd by Merit.

The Lloyd Rule 10b5-1 Trading Plan will terminate on February 26, 2027 , unless terminated earlier pursuant to the terms of the Lloyd Rule 10b5-1 Trading Plan.

Other than with respect to the Parra Rule 10b5-1 Trading Plan and the Lloyd Rule 10b5-1 Trading Plan, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K, during the three-month period ended June 30, 2026.

Incorporated by Reference

1 unchanged sentence

August 9, 2018

Fourth Amended and Restated Bylaws.*

Consulting Agreement, dated January 7, 2026, between Merit Medical Systems, Inc.

Lampropoulos.†*

February 24, 2026

Amended and Restated Employment Agreement, dated May 1, 2025, between Merit Medical Systems, Inc.

and Raul Parra.†

Amended and Restated Employment Agreement, dated May 1, 2025, between Merit Medical Systems, Inc.

and Michel J.

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2026, between Merit Medical Systems, Inc.

and Martha Aronson.†

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2026, between Merit Medical Systems, Inc.

and Raul Parra.†

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2026, between Merit Medical Systems, Inc.

and Brian Lloyd.†

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2026, between Merit Medical Systems, Inc.

and Neil Peterson.†

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2026, between Merit Medical Systems, Inc.

and Mike Voigt.†